Abstract
Introduction
Cardiovascular diseases are the leading cause of death in the developed countries. Atherosclerosis is the major contributor to the pathogenesis of acute myocardial and cerebral thrombosis [1] . [1] . As the lesion becomes more bulky, atherosclerotic plaques may develop into plaque that is vulnerable to rupture (vulnerable plaque) and its rupture causes the formation of thrombosis [1] .
Atherosclerosis is a chronic, progressive inflammatory disease, which develops in response to endothelial injury. Initiation of the injury is brought by pro-inflammatory cytokines and risk factors, such as hypercholesterolemia, smoking, hypertension and diabetes [2]. Atherosclerotic arteries have morphologically raised lesions referred to as atherosclerotic plaques. They are characterized by the deposition of lipids, inflammatory cells like macrophages and T lymphocytes, vascular smooth muscle cells and connective tissue within the arterial wall
Conventional atherosclerosis imaging with x-ray angiography reveals only the severity of luminal narrowing of vessel and does not take into account the plaque biology, including vulnerable plaque [3] . Although some catheter-based techniques, such as intravascular ultrasound, can provide information on the composition of individual plaques, their invasive nature limits their use [4] . Therefore, there still remains a great need for novel diagnostic tools to assess non-invasively molecular changes associated with atherosclerosis and to understand plaque nature for detecting whether the plaque is vulnerable to impending rupture or stable atherosclerotic lesion.
Phage-displayed peptide library has been used to find novel peptide ligands that target specific organs, tumours, and tumour blood vessels [5] [6] [7] . Such tissue-specificity is based on the molecular diversity of tissues and blood vessels. Angiogenic tumour blood vessels, for example, are morphologically tortuous and leaky and carry distinct molecular markers like ␣v␤3 integrin on the endothelium [8, 9] , leading to the identification of the tumour vasculature-homing Arg-Gly-Asp (RGD) peptide [10] . (vasa vasorum) in the arterial wall [1] . [11] . Here we used phage display technology and identified peptides that selectively recognize and home to atherosclerotic plaques in vivo. Fig. 2A and B, insets) . The CRKRLDRNC peptide homed to atherosclerotic plaques of three Ldlr -/-mice ( Fig. 2A) , while the NSSSVDK control peptide, the sequence that is displayed by the nonrecombinant T7 phage, did not (Fig. 2B) . The homing peptide bound to the endothelium overlying a lesion, but not to the endothelium not directly overlying the lesion (non-atherosclerotic area) of the same mouse (Fig. 2C) . The CRKRLDRNC peptide did not home to other organs such as brain (Fig. 2M) 
Similarly, atherosclerotic blood vessels have characteristic molecular changes, including increased expression of vascular cell adhesion molecule-1 (VCAM-1) and P-selectin on endothelial surface and the formation of new blood vessels

Identification of targeting ligands that home specifically to atherosclerotic plaques may provide numerous potential applications including selective delivery of therapeutic agents and imaging probes to plaque tissues. Such tissue-specific homing ligands may also lead to the identification of novel receptors and new drug targets at the lesion. Peptides have several advantages over antibodies as a targeting moiety, including better organ penetration and less chance of unintended immune reaction
Materials and methods
Animals
as well as liver and lung (not shown). Similar results were obtained when the peptide was circulated for 2 hr (data not shown). To see the type of cellular components to which the homing peptide bound in vivo, we analysed the localization of the CRKRL-DRNC peptide at the atherosclerotic plaques of Ldlr
-/-mice. (Fig. 2J-L) . Interestingly, the homing peptide also could bind to early atherosclerotic lesions of relatively small size (Fig. 2G-I (Fig. 2N) .
Immunostaining using antibodies against the cell-type specific markers showed that the fluorescent CRKRLDRNC peptide colocalized with endothelial cells (vWF) along the surface of atherosclerotic plaques (Fig. 2D-F) and also macrophages (Mac3) inside the plaques
In contrast, 123 I-CLEVSRKNC uptake was negligible at aortas of both Ldlr -/-and control mice (Fig. 2O) . The uptake signal in Fig. 2N was observed diffusely, rather than focally, along the aortas, which reflects the radiating property of radioisotope signals. Fig. 3 D-F) , macrophages (CD68) (Fig. 3G-I (Fig. 5A) , while it is expressed at high levels in the IL-4R-transfected cells (Fig. 5D) . The fluorescent CRKDL-DRNC peptide did not bind to the mock-transfected CHO-K1 cells (Fig. 5B) . In contrast, the CRKDLDRNC peptide strongly bound to the CHO-K1 cells over-expressing IL-4R on the surface (Fig. 5D-F) , while the binding of the NSSSVDK control peptide to the cells was minimal (Fig. 5C) . (Fig. 5G-I) , whereas the NSSSVDK control peptide did not (Fig. 5O) (Fig. 5J) . Accordingly, the binding of the CRKRLDRNC peptide to the cells was decreased to minimal levels (Fig. 5K-L) . 
The CRKRLDRNC peptide overlay onto human atherosclerotic plaques
To examine whether the CRKRLDRNC peptide selectively binds to human atherosclerotic plaques, we performed peptide overlay onto frozen sections of primary tissues. Oil red-O staining demonstrated characteristic lipid deposition at atherosclerotic plaques (Fig. 3A). The fluorescein-labelled CRKRLDRNC peptide bound to the sections of eight atherosclerotic tissues from human arteries (Fig. 3B), while little binding of the NSSSVDK control peptide was observed (Fig. 3C). In similar to the localization of the peptide at mouse tissues in vivo, the CRKRLDRNC peptide co-localized with endothelial cells (CD31) (
Co-localization of the peptide and IL-4R was also observed by peptide overlay on two human atherosclerotic plaques (Fig. 4E-G). IL-4R was abundant in human atherosclerotic tissues (Fig. 4F), while being at negligible levels in a normal arterial tissue (Fig. 4H-I). These findings suggest that IL-4R is a candidate receptor for the peptide homing to atherosclerotic plaques. To further investigate the hypothesis that IL-4R is the corresponding receptor for the homing of the CRKRLDRNC peptide, we transiently transfected the human IL-4R expression vector into CHO-K1 cells. Immunostaining showed that IL-4R is present at negligible levels in the parental (data not shown) or mock-transfected CHO-K1 cells
Next, we carried out the knockdown of IL-4R using siRNA in IL-4R-expressing cells. We examined several cell lines for endogenous expression of IL-4R on the cell surface. Immunostaining of IL-4R showed the expression of IL-4R at high levels in HT-1376 human bladder tumour cells (Fig. 5G) and HUVEC human endothelial cells (data not shown). The fluorescent CRKRLDRNC peptide strongly bound to HT-1376 cells
. The binding of the fluorescent CRKRLDRNC peptide to the cells was completely blocked by the unlabeled (not fluorescent) CRKRLDRNC peptide given at 100-fold molar excess (data not shown). Transfection of the siRNA against human IL-4R almost suppressed its expression in HT-1376 cells
The box in (A) marks an area of the artery that was examined microscopically in (B-L). (B and C) Peptide overlay was performed with fluorescein-labelled CRKRLDRNC peptide (B) or NSSSVDK control peptide (C). (D-L) The CRKRLDRNC peptide overlay (D, G and J), costaining for CD31 (E), CD68 (H) and ␣-SMA (K), and the merges (F, I and L). Note that the
ing (C) and the merge (D). (E-G) The CRKRLDRNC peptide overlay onto human atherosclerotic plaques (E), IL-4R staining (F) and the merge (G).
Note that the CRKRLDRNC peptide co-localized with IL-4R, which was present at mouse and human atherosclerotic plaques (arrows in D and G). (H) H&E and (I) IL-4R staining of a human normal arterial tissue. DAPI staining for nucleus was shown in blue. Scale bars represent 20 µm (B-G) and 100 µm (I).
Control siRNA did not affect the expression of IL-4R in HT-1376 cells (Fig. 5M) and also the binding of the CRKRLDRNC peptide to the cells (Fig. 5N) [17, 18] . IL-4R also exits on T lymphocytes and vascular smooth muscle cells [19, 20] . First, we demonstrated that the CRKRLDRNC peptide injected into mice or subjected to peptide overlay onto human primary tissue co-localized with IL-4R at atherosclerotic plaques. We also demonstrated the up-regulation of IL-4R at both mouse and human atherosclerotic tissues, which was consistent with a previous study [21] . Second 
4R-transfected CHO-K1 cells (C) and HT-1376 cells (O). IL-4R staining, the CRKRLDRNC peptide binding, and the merges in IL-4R-transfected CHO-K1 cells (D-F), HT-1376 cells (G-I), and IL-4R siRNA-transfected HT-1376 cells (J-L). IL-4R staining (M) and
